Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 14, Issue 5, Pages 228-235Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/S1043-2760(03)00076-6
Keywords
-
Categories
Funding
- NINDS NIH HHS [NS 33668, NS 20020, NS 03521] Funding Source: Medline
Ask authors/readers for more resources
Women are protected from stroke in their early years relative to men. This native neuroprotection is lost within ten years of the menopause, an observation commonly attributed to loss of estrogen with age. Data are now available from large, randomized, clinical trials that question the use of hormone replacement therapy (HRT) for either the primary or secondary prevention of vascular disease and stroke. In contrast to these studies of disease prevention, evidence from the bench suggests that estrogen is a potent neuroprotectant, demonstrating cell salvage from ischemic death pathways. This apparent dichotomy between the limitation of HRT in ameliorating complex disease development vs the excellent performance of estradiol in containing experimental brain damage remains to be understood.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available